Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04664153 · ClinicalTrials.gov registry record · Phase 2
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
A Phase 2 study of Atopic Dermatitis and Plaque Psoriasis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 20
- Study locations
NCT04664153: Completed Phase 2 study of Atopic Dermatitis and Plaque Psoriasis, sponsored by Pfizer.
NCT04664153 is a Phase 2 study of Atopic Dermatitis and Plaque Psoriasis that has completed, run by Pfizer. The registered enrollment target is 104 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04664153, a Phase 2 study of Atopic Dermatitis and Plaque Psoriasis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
Primary Outcome
EASI evaluated severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upo
Conditions Studied
Interventions
- DRUG PF-07038124 ointment
- DRUG Vehicle ointment
Study Locations (20)
Florida
- Renaissance Research and Medical Group - Cape Coral
- Olympian Clinical Research - Clearwater
- Moonshine Research Center, Inc. - Doral
- Clinical Neuroscience Solutions - Orlando
- Center for Clinical Studies - Tampa
Texas
- studies in Dermatology, LLC - Cypress
- Center for Clinical Studies - Houston
- Center for Clinical Studies, LTD. LLP - Webster
Ontario
- Dermatrials Research Inc. - Hamilton
- Lynderm Research Inc. - Markham
- DermEdge Research - Mississauga
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
- The Indiana Clinical Trials Center, PC - Plainfield
California
- First OC Dermatology - Fountain Valley
Michigan
- Henry Ford Medical Center, New Center One - Detroit
North Carolina
- M3 Wake Research, Inc. - Raleigh
Oregon
- Oregon Dermatology and Research Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2021-08-18 |
| Phase | Phase 2 |
What the finished NCT04664153 record still lists
NCT04664153 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which PF-07038124 ointment is the first listed.
NCT04664153 names 20 study sites across 11 states, led by Florida, Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT04664153 about?
NCT04664153 is a clinical study titled "Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis". This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
What is the current status of trial NCT04664153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2020-12-21. Estimated completion is 2021-08-18.
What conditions does trial NCT04664153 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Plaque Psoriasis.
What interventions are being tested in trial NCT04664153?
The interventions under investigation include: PF-07038124 ointment (DRUG), Vehicle ointment (DRUG).
Who is sponsoring clinical trial NCT04664153?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04664153 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04664153's enrollment target sits among peer trials
104 82nd of 150 higher than 69 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI